Guardant Health, Inc. has recently announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Guardant360^® CDx liquid biopsy test as a companion diagnostic to select patients with unresectable (inoperable) advanced or recurrent non-small cell lung cancer (NSCLC) with HER2 (ERBB2) mutations that has progressed after chemotherapy for treatment with ENHERTU^® (trastuzumab deruxtecan). ENHERTU is a specifically engineered HER2-directed antibody drug conjugate developed by Daiichi Sankyo.

Read the full press release here: https://investors.guardanthealth.com/press-releases/press-releases/2023/Guardant-Health-Receives-Regulatory-Approval-in-Japan-for-Guardant360-CDx-as-Companion-Diagnostic-to-ENHERTU-for-Treatment-of-Non-Small-Cell-Lung-Cancer-Patients-with-HER2-Mutations/default.aspx

Visit us at https://lnkd.in/dVEkKyRC to find out more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer.

#guardanthealthamea #guardanthealth #liquidissolid #medicaloncologists #pressrelease #WCLC2023 #comprehensivegenomicprofiling #lungcancer #NSCLC #guardant360 #guardant360CDx #companiondiagnostic #CDx #precisiononcology #liquidbiopsy